Leukemia Research
Volume 24, Issue 7 , Pages 559-565 , July 2000

Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia

  • Jennifer E Bushman

      Affiliations

    • Department of Chemistry, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-3290, USA
    • ,
  • Diane Palmieri

      Affiliations

    • Department of Pathology and Laboratory, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7525, USA
    • ,
  • Herbert C Whinna

      Affiliations

    • Department of Pathology and Laboratory, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7525, USA
    • Center for Thrombosis and Hemostasis, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7015, USA
    • ,
  • Frank C Church

      Affiliations

    • Department of Pathology and Laboratory, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7525, USA
    • Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365, USA
    • Department of Medicine, Division of Hematology-Oncology, 932 Mary Ellen Jones Bldg., The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7035, USA
    • Center for Thrombosis and Hemostasis, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7015, USA
    • Corresponding Author InformationCorresponding author. At Division of Hematology-Oncology, Department of Medicine, 932 Mary Ellen Jones Bldg., The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7015, USA. Tel.: +1-919-9663311; fax: +1-919-9667639

Received 20 September 1999 ,Accepted 21 January 2000.

References 

  1. Rivera GK, Crist WM. Acute lymphoblastic /leukemia. In:  Handlin RI,  Stossel TP,  Lux SE editor. Blood: Principles and Practice of Hematology. Philadelphia: Lippincott; 1995;p. 743
  2. Cortes JE, Kantarjian HM. Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy. Cancer. 1995;76:2393
  3. Freedman AS, Nadler LM. In: Braunwald E, Fauci AS, Isselbacher KJ, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Malignancies of Lymphoid Cells (ch. 113). New York Harrison’s Online http://www.harrisonsonline.com/hill-bin/Chapters.cgi
  4. Pui C-H, Evans WE. Acute lymphoblastic leukemia. New Engl. J. Med. 1998;339:605
  5. Bauer KA, Teitel JM, Rosenberg RD. l-asparaginase induced antithrombin III deficiency: evidence against the production of a hypercoagulable state. Thromb. Res. 1983;29:437
  6. Anderson N, Lokich JJ, Tullis JL. l-asparaginase effect on antithrombin-III levels. Med. Pediatr. Oncol. 1979;7:335
  7. Pitney WR, Phadke KP, Dean S. Antithrombin III deficiency during asparaginase therapy. Lancet. 1980;I:493
  8. Vellenga E, Mulder NH, Nieweg HO. Antithrombin III deficiency during asparaginase therapy. Lancet. 1980;I:649
  9. Priest JR, Ramsay NKC, Bennett AJ, Krivit W, Edson JR. The effect of l-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia. J. Pediatr. 1982;100:990
  10. Liebman HA, Wada JK, Patch MJ, McGehee W. Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with l-asparaginase. Cancer. 1982;50:451
  11. Homans AC, Rybak ME, Baglini RL, Tiarks C, Steiner ME, Forman EN. Effect of l-asparaginase administration on coagulation and platelet function in children with leukemia. J. Clin. Oncol. 1987;5:811
  12. Shapiro AD, Clarke SL, Christian JM, Odom LF, Hathaway WE. Thrombosis in children receiving l-asparaginase. Determining patients at risk. Am. J. Pediatr. Hematol. Oncol. 1993;15:400
  13. Andrew M, Brooker L, Mitchell L. Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia. Blood Coagul. Fibrinolysis. 1994;5:S24
  14. Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in l-asparaginase-induced antithrombin III deficiency. Blood. 1994;83:386
  15. Nowak-Gottl U, Boos J, Wolff JEA, Lill H, Veltmann H, Werber G, et al. Asparaginase decreases clotting factors in vitro: a possible pitfall?. Int. J. Clin. Lab. Res. 1995;25:146
  16. Mitchell LG, Sutor AH, Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Semin. Thromb. Hemost. 1995;21:390
  17. Roberts HR, Lozier JN. New perspectives on the coagulation cascade. Hosp. Pract. 1992:97.
  18. Church FC, Cunningham DD, Ginsburg D, Hoffman M, Stone SR, Tollefsen DM, editors. Chemistry and Biology of Serpins. New York: Plenum Press, 1997.
  19. Nowak-Gottl U, Kuhn N, Wolff JEA, Boos J, Kehrel B, Rath B, et al. Inhibition of hypercoagulation by antithrombin substitution in E. coli l-asparaginase-treated children. Eur. J. Haematol. 1996;56:35
  20. Nowak-Gottl U, Rath B, Binder M, Hassel J-U, Wolff J, Husemann S, et al. Inefficacy of fresh frozen plasma in the treatment of l-asparaginase-induced coagulation factor deficiencies during ALL induction therapy. Haematologica. 1995;80:451
  21. Halton JM, Mitchell LG, Vegh P, Eves M, Andrew ME. Fresh frozen plasma has no beneficial effect on the hemostatic system in children receiving l-asparaginase. Am. J. Hematol. 1994;47:157
  22. Pogliani EM, Parma M, Baragetti I, Mostarda G, Rivolta F, Maffe P, et al. l-asparaginase in acute lymphoblastic leukemia treatment: the role of human antithrombin III concentrates in regulating the prothrombotic state induced by therapy. Acta Haematol. 1995;93:5
  23. Griffith MJ, Noyes CM, Church FC. Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. J. Biol. Chem. 1985;260:2218
  24. Church FC, Whinna HC. Rapid sulfopropyl-disk chromatographic purification of bovine and human thrombin. Anal. Biochem. 1986;157:77
  25. Frohwein YZ, Friedman M, Reizer J, Grossowicz N. Sensitive and rapid assay for l-asparaginase. Nat. New Biol. 1971;230:158
  26. Capizzi RL, Handschumacher RE. Asparaginase. In:  Holland JR,  Frei E editor. Cancer Medicine. Lea & Fibiger; 1973;p. 850
  27. Whinna HC, Blinder MA, Szewczyk M, Tollefsen DM, Church FC. Role of lysine 173 in heparin binding to heparin cofactor II. J. Biol. Chem. 1991;266:8129
  28. Pratt CW, Tobin RB, Church FC. Interaction of heparin cofactor II with neutrophil elastase and cathepsin G. J. Biol. Chem. 1990;265:6092
  29. Bauman SJ, Church FC. Enhancement of heparin cofactor II anticoagulant activity. J. Biol. Chem. 1999;274:34556
  30. Odegard OR, Lie M, Abildgaard U. Antifactor Xa activity measured with amidolytic methods. Haemostasis. 1976;5:265
  31. Palmieri D, Watson JM, Rinehart CA. Age-related expression of PEDF/EPC-1 in human endometrial stromal fibroblasts: implications for interactive senescence. Exp. Cell Res. 1999;247:142
  32. Mossmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 1983;83:55
  33. Watson JM, Parrish EA, Rinehart CA. Selective potentiation of gynecologic cancer cell growth in vitro by electromagnetic fields. Gynecol. Oncol. 1998;71:64
  34. Cairo MS. Adverse reactions of l-asparaginase. Am. J. Pediatr. Hematol./Oncol. 1982;4:335
  35. Conard J, Cazenave B, Maury J, Horellou MH, Samama M. l-asparaginase, antithrombin III, and thrombosis. Lancet. 1980;I:1091
  36. Capizzi RL, Bertino JR, Skeel RT, Creasey WA, Zanes R, Olayon C, et al. l-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann. Intern. Med. 1971;74:893
  37. Humphries JE. Thromophilia and complex acquired deficiencies of antithrombin, protein C, and protein S. Semin. Hematol. 1995;32:8

PII: S0145-2126(00)00017-5

Leukemia Research
Volume 24, Issue 7 , Pages 559-565 , July 2000

Article Tools

* Image Usage & Resolution